Korean J Obstet Gynecol.  2010 Nov;53(11):1007-1013. 10.5468/kjog.2010.53.11.1007.

Outcomes after bleomycin, etoposide and cisplatin combination chemotherapy in patients with ovarian yolk sac tumor

• Kim JY
• Shin YJ
• Moon JW
• Park JY
• Kim DY
• Lee JH
• Kim JH
• Kim YM
• Kim YT
• Nam JH

• KMID: 1836715
• DOI: http://doi.org/10.5468/kjog.2010.53.11.1007

Abstract

OBJECTIVE
The aim of this study was to evaluate the oncologic and reproductive outcomes of patients with ovarian yolk sac tumor after bleomycin, etoposide, cisplatin (BEP) chemotherapy following surgery.
METHODS
Of 145 patients with histologically confirmed malignant ovarian germ cell tumor, 43 had yolk sac tumor and received BEP chemotherapy after surgery. A retrospective analysis of these patients was performed.
RESULTS
The mean age of 43 patients was 24.8 years (range, 7 to 59 years). Thirty eight patients were nulliparous. Of 179 BEP chemotherapy cycles, grade 1~2 hematologic and non-hematologic adverse events occurred in 46 cycles in 21 patients. Thirty nine patients showed complete remission, 1 patient showed partial remission, and 3 patient had progressive disease during BEP chemotherapy. After median follow-up time of 57 months (range, 3 to 153 months), 5 patients had recurrent disease and three of them died of disease. The 5-year recurrence free survival rate and overall survival rate were 86% and 94%, respectively. After chemotherapy, all but one premenarchal patients had normal menstruation. Of them 5 patients tried to conceive and 3 of them succeeded in pregnancy.
CONCLUSION
BEP chemotherapy was very safe and effective in patients with ovarian yolk sac tumor. Survival outcomes are excellent and reproductive outcomes are promising after BEP chemotherapy.

Keyword

Malignant ovarian germ cell tumor; Yolk sac tumor; Bleomycin; Etoposide; Cisplatin

MeSH Terms

Bleomycin
Cisplatin
Drug Therapy, Combination
Endodermal Sinus Tumor
Etoposide
Female
Follow-Up Studies
Humans
Menstruation
Neoplasms, Germ Cell and Embryonal
Pregnancy
Recurrence
Retrospective Studies
Survival Rate
Yolk Sac
Bleomycin
Cisplatin
Etoposide

Figure

• 

  Figure 1 Disease-free survival (A) and overall survival (B) of 43 patients with ovarian yolk sac tumor.

Reference

1. Kurman RJ, Norris HJ. Malignant germ cell tumors of the ovary. Hum Pathol. 1977. 8:551–564.

2. Creasman WT, DiSaia PJ. Screening in ovarian cancer. Am J Obstet Gynecol. 1991. 165:7–10.

3. Nawa A, Obata N, Kikkawa F, Kawai M, Nagasaka T, Goto S, et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol. 2001. 184:1182–1188.

4. Berek JS, Hacker NF. Laparoscopy in the management of patients with ovarian carcinoma. Clin Obstet Gynaecol. 1983. 10:213–222.

5. Ayhan A, Taskiran C, Bozdag G, Altinbas S, Altinbas A, Yuce K. Endodermal sinus tumor of the ovary: the Hacettepe University experience. Eur J Obstet Gynecol Reprod Biol. 2005. 123:230–234.

6. Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol. 2008. 111:106–110.

7. Kim SR, Na JH, Kim JH, Chun DJ, Kim YM, Kim YT, et al. Malignant germ cell tumors of the ovary: a clinical and pathological study of 42 cases. Korean J Gynecol Oncol Colposc. 1998. 9:289–299.

8. Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A, Kohler MF. Malignant germ cell tumors of the ovary. Obstet Gynecol. 2000. 95:128–133.

9. Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994. 12:701–706.

10. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol. 1990. 8:715–720.

11. Peckham MJ, Barrett A, Liew KH, Horwich A, Robinson B, Dobbs HJ, et al. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer. 1983. 47:613–619.

12. Selvaggi SM. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Arch Pathol Lab Med. 2000. 124:477.

13. Williams SD. Ovarian germ cell tumors: an update. Semin Oncol. 1998. 25:407–413.

14. Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004. 95:695–700.

15. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev. 2008. 34:427–441.

16. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003. 14:91–96.

17. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987. 316:1435–1440.

18. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991. 338:359–363.

19. De Palo G, Pilotti S, Kenda R, Ratti E, Musumeci R, Mangioni C, et al. Natural history of dysgerminoma. Am J Obstet Gynecol. 1982. 143:799–807.

20. Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni C. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol. 1995. 86:367–372.

21. Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980. 93:109–114.

22. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990. 1:183–188.

23. Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol. 1988. 6:270–275.